Sellas Life Sciences Group (SLS)
NASDAQ:SLS
SLS Stock Chart & Stats
$4.11
-$0.10(-9.43%)
At close: 4:00 PM EST
$4.11
-$0.10(-9.43%)
Day’s Range― - ―
52-Week Range$0.95 - $6.14
Previous CloseN/A
Volume1.43M
Average Volume (3M)7.11M
Market Cap
$897.01M
Enterprise Value$640.61M
Total Cash (Recent Filing)$71.89M
Total Debt (Recent Filing)$1.00M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
May 19, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding179,582,580
10 Day Avg. Volume8,867,889
30 Day Avg. Volume7,112,577
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)5.80
Price to Sales (P/S)0.00
P/FCF Ratio-14.48
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-31.06
Forecast
1Y Price Target
$10.00Price Target Upside143.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$36.13M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutUpcoming top-line readout from the Phase 3 REGAL study of galinpepimut-S represents a major potential catalyst if results show a survival benefit.
Financial PositionStrengthened cash position driven by available cash and warrant exercise proceeds reduces near-term financing risk and supports ongoing development programs.
Indication ExpansionInitiation of a Phase 2 triplet study of SLS009 in first-line unfit AML expands potential commercial opportunity by moving the drug into an earlier treatment setting.
Bears Say
Development And Regulatory RiskDrug development in relapsed or refractory AML has historically produced modest survival gains, which increases development and regulatory risk for AML-focused programs.
Interim Data UncertaintyBlinded and pooled interim data from REGAL limits confidence in efficacy signals and increases uncertainty about the true treatment effect.
Reliance On Historical ComparatorsInterim survival trends compared with historical outcomes can overstate benefit and risk misleading interpretation of clinical efficacy.
SELLAS Life Sciences Group News
SLS FAQ
What was Sellas Life Sciences Group’s price range in the past 12 months?
Sellas Life Sciences Group lowest stock price was $0.95 and its highest was $6.14 in the past 12 months.
What is Sellas Life Sciences Group’s market cap?
Sellas Life Sciences Group’s market cap is $897.01M.
When is Sellas Life Sciences Group’s upcoming earnings report date?
Sellas Life Sciences Group’s upcoming earnings report date is May 19, 2026 which is in 55 days.
How were Sellas Life Sciences Group’s earnings last quarter?
Sellas Life Sciences Group released its earnings results on Mar 19, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.063 by $0.013.
Is Sellas Life Sciences Group overvalued?
According to Wall Street analysts Sellas Life Sciences Group’s price is currently Undervalued.
Does Sellas Life Sciences Group pay dividends?
Sellas Life Sciences Group does not currently pay dividends.
What is Sellas Life Sciences Group’s EPS estimate?
Sellas Life Sciences Group’s EPS estimate is -0.06.
How many shares outstanding does Sellas Life Sciences Group have?
Sellas Life Sciences Group has 179,582,580 shares outstanding.
What happened to Sellas Life Sciences Group’s price movement after its last earnings report?
Sellas Life Sciences Group reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.063. Following the earnings report the stock price went down -8.462%.
Which hedge fund is a major shareholder of Sellas Life Sciences Group?
Currently, no hedge funds are holding shares in SLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SELLAS Life Sciences Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (143.31% Upside)
$10.00 (143.31% Upside)
Blogger Sentiment
Bullish
SLS Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.6%
Last 30 Days ▲ 19.8%
Last 30 Days ▲ 19.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
306.09%
12-Months-Change
Fundamentals
Return on Equity
-63.06%
Trailing 12-Months
Asset Growth
299.07%
Trailing 12-Months
Company Description
Sellas Life Sciences Group
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
SLS Stock 12 Month Forecast
Average Price Target
$10.00
▲(143.31% Upside)
Technical Analysis
Galectin Therapeutics
―
Voyager Therapeutics
―
Tiziana Life Sciences
―
Diamedica Therapeutics
―
Black Diamond Therapeutics
―
Ownership Overview
1.60% Insiders
7.24% Mutual Funds
3.01% Other Institutional Investors
79.74% Public Companies and Individual Investors